Literature DB >> 23147509

Post-insult ibuprofen treatment attenuates damage to the serotonergic system after hypoxia-ischemia in the immature rat brain.

Julie A Wixey1, Hanna E Reinebrant, Kathryn M Buller.   

Abstract

There is currently no therapeutic intervention to stem neonatal brain injury after exposure to hypoxia-ischemia (HI). Potential neuroprotective treatments that can be delivered postinsult that target neuroinflammation and are safe to use in neonates are attractive. One candidate is ibuprofen. Ibuprofen is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and is used in neonates to treat patent ductus arteriosus. We investigated whether ibuprofen can inhibit neuroinflammation and attenuate neuronal damage manifested in a rodent model of preterm HI. Postnatal day 3 (P3) rat pups were subjected to HI (right carotid artery ligation, 30 minutes 6% O₂). Ibuprofen was then administered daily for 1 week (100 mg/kg P3 2 hours after HI, 50 mg/kg P4-P9; subcutaneously). Ibuprofen treatment prevented the P3 HI-induced reductions in brain serotonin levels, serotonin transporter expression, and numbers of serotonergic neurons in the dorsal raphé nuclei on P10. Ibuprofen also significantly attenuated P3 HI-induced increases in brain cyclooxygenase 2 protein expression, interleukin-1β, and tumor necrosis factor levels, as well as the increase in numbers of activated microglia. Thus, ibuprofen administered after an HI insult may be an effective pharmacologic intervention to reduce HI-induced neuronal brain injury in the preterm neonate by limiting the effects of neuroinflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147509     DOI: 10.1097/NEN.0b013e318277d4c7

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

Review 1.  Therapeutic potential to reduce brain injury in growth restricted newborns.

Authors:  Julie A Wixey; Kirat K Chand; Lily Pham; Paul B Colditz; S Tracey Bjorkman
Journal:  J Physiol       Date:  2018-05-23       Impact factor: 5.182

2.  Disruption to the 5-HT7 Receptor Following Hypoxia-Ischemia in the Immature Rodent Brain.

Authors:  Julie A Wixey; Hanna E Reinebrant; Kirat K Chand; Kathryn M Buller
Journal:  Neurochem Res       Date:  2018-01-22       Impact factor: 3.996

3.  Neurovascular Unit Alterations in the Growth-Restricted Newborn Are Improved Following Ibuprofen Treatment.

Authors:  Kirat K Chand; Stephanie M Miller; Gary J Cowin; Lipsa Mohanty; Jany Pienaar; Paul B Colditz; Stella Tracey Bjorkman; Julie A Wixey
Journal:  Mol Neurobiol       Date:  2021-11-26       Impact factor: 5.590

4.  Microglia modulate brainstem serotonergic expression following neonatal sustained hypoxia exposure: implications for sudden infant death syndrome.

Authors:  P M MacFarlane; C A Mayer; D G Litvin
Journal:  J Physiol       Date:  2016-02-21       Impact factor: 5.182

5.  Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy.

Authors:  Thomas Krøigård; Athanasios Metaxas; Martin Wirenfeldt; Bente Finsen
Journal:  Exp Brain Res       Date:  2019-08-06       Impact factor: 1.972

6.  Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.

Authors:  Ashish Singh; Pratibha Tripathi; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2015-12-12       Impact factor: 5.590

7.  Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder.

Authors:  Bombi Lee; Bongjun Sur; Mijung Yeom; Insop Shim; Hyejung Lee; Dae-Hyun Hahm
Journal:  Korean J Physiol Pharmacol       Date:  2016-06-23       Impact factor: 2.016

8.  Targeting inflammation to reduce brain injury in growth restricted newborns: A potential treatment?

Authors:  Julie A Wixey; Paul B Colditz; Stella Tracey Björkman
Journal:  Neural Regen Res       Date:  2017-11       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.